-
Something wrong with this record ?
Idiopathic inflammatory myopathies
IE. Lundberg, M. Fujimoto, J. Vencovsky, R. Aggarwal, M. Holmqvist, L. Christopher-Stine, AL. Mammen, FW. Miller
Language English Country Great Britain
Document type Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review
NLK
ProQuest Central
from 2015-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2015-01-01 to 1 year ago
- MeSH
- Autoimmune Diseases * diagnosis MeSH
- Autoantibodies MeSH
- Dermatomyositis * pathology therapy MeSH
- Humans MeSH
- Myositis, Inclusion Body * pathology MeSH
- Myositis * diagnosis pathology MeSH
- Muscle Weakness MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, N.I.H., Intramural MeSH
Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.
Department of Dermatology Osaka University Graduate School of Medicine Suita Japan
Deptartment of Rheumatology 1st Medical Faculty Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011754
- 003
- CZ-PrNML
- 005
- 20220506131506.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41572-021-00321-x $2 doi
- 035 __
- $a (PubMed)34857798
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden. ingrid.lundberg@ki.se $1 https://orcid.org/0000000260689212
- 245 10
- $a Idiopathic inflammatory myopathies / $c IE. Lundberg, M. Fujimoto, J. Vencovsky, R. Aggarwal, M. Holmqvist, L. Christopher-Stine, AL. Mammen, FW. Miller
- 520 9_
- $a Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.
- 650 _2
- $a autoprotilátky $7 D001323
- 650 12
- $a autoimunitní nemoci $x diagnóza $7 D001327
- 650 12
- $a dermatomyozitida $x patologie $x terapie $7 D003882
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a svalová slabost $7 D018908
- 650 12
- $a myozitida $x diagnóza $x patologie $7 D009220
- 650 12
- $a myozitida s inkluzními tělísky $x patologie $7 D018979
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Fujimoto, Manabu $u Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan $1 https://orcid.org/0000000230624872
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic $u Deptartment of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000208510713 $7 jo20000080529
- 700 1_
- $a Aggarwal, Rohit $u UPMC Myositis Center, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA
- 700 1_
- $a Holmqvist, Marie $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden $u Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000189965260
- 700 1_
- $a Christopher-Stine, Lisa $u Johns Hopkins Myositis Center, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA $1 https://orcid.org/0000000271507306
- 700 1_
- $a Mammen, Andrew L $u National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA $u Departments of Neurology and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA $1 https://orcid.org/0000000337323252
- 700 1_
- $a Miller, Frederick W $u Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
- 773 0_
- $w MED00200655 $t Nature reviews. Disease primers $x 2056-676X $g Roč. 7, č. 1 (2021), s. 86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34857798 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506131458 $b ABA008
- 999 __
- $a ok $b bmc $g 1789377 $s 1162952
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 7 $c 1 $d 86 $e 20211202 $i 2056-676X $m Nature reviews. Disease primers $n Nat Rev Dis Primers $x MED00200655
- LZP __
- $a Pubmed-20220425